This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alderton, P. M. Articles by Green, M. D. Search for Related Content PubMed PubMed Citation Articles by Alderton, P. M. Articles by Green, M. D.

Comparative Study of Doxorubicin, Mitoxantrone, and Epirubicin in Combination with ICRF-187 (ADR-529) in a Chronic Cardiotoxicity Animal Model¹

Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, 3050 [P. M. A., M. D. G.], and Department of Pathology, University of Melbourne, Parkville, Victoria, 3052 [J. G.], Australia

In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in an effort to identify and compare their mechanism(s) of toxicity. In addition, the cardioprotective ability of ICRF-187 [(±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] with each anticancer drug was evaluated in this model. The antioxidant capacity (superoxide dismutase, reduced glutathione, catalase, and glutathione peroxidase) was assessed following drug treatment.

Five-week-old BALB/c mice received weekly i.p. injections of each drug or the drug and ICRF-187 over a 3-month period. ICRF-187 was administered 30 min prior to the anticancer drug. The hearts were examined by electron and light microscopy to assess subcellular changes, and the cardiac and hepatic antioxidant levels were measured concurrently. Chronic treatment with these drugs or each combined with ICRF-187 did not change the antioxidant levels relative to the control values. However, all three drugs caused cardiac damage during chronic exposure. Both epirubicin and mitoxantrone caused less severe damage than doxorubicin, and epirubicin was the least cardiotoxic of the three. ICRF-187 was cardioprotective for epirubicin and doxorubicin but not for mitoxantrone. These results suggest epirubicin acts by a mechanism similar to that of doxorubicin that is probably mediated by oxygen-free radicals, while mitoxantrone acts by a different mechanism to cause cardiotoxicity.

¹ This study was supported by a grant from the Anticancer Council of Victoria.

² To whom requests for reprints should be addressed, at Department of Medical Oncology, c/o Post Office, Royal Melbourne Hospital, Victoria, 3050, Australia.

Received 6/ 7/91. Accepted 10/18/91.

This article has been cited by other articles:

				P. Fumoleau, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results Ann. Onc., January 1, 2006; 17(1): 85 - 92. [Abstract] [Full Text] [PDF]

				K. A. Conklin Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity Integr Cancer Ther, June 1, 2005; 4(2): 110 - 130. [Abstract] [PDF]

				J. Bonneterre, H. Roche, P. Kerbrat, P. Fumoleau, M.-J. Goudier, P. Fargeot, P. Montcuquet, P. Clavere, J.-C. Barats, A. Monnier, et al. Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group J. Clin. Oncol., August 1, 2004; 22(15): 3070 - 3079. [Abstract] [Full Text] [PDF]

				E. F. Petricoin, V. Rajapaske, E. H. Herman, A. M. Arekani, S. Ross, D. Johann, A. Knapton, J. Zhang, B. A. Hitt, T. P. Conrads, et al. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection Toxicol Pathol, January 1, 2004; 32(1_suppl): 122 - 130. [Abstract] [PDF]

				W. Darko, A. L Smith, E. L King, and S. J Grethlein Mitoxantrone-induced cardiotoxicity Journal of Oncology Pharmacy Practice, March 1, 2001; 7(1): 47 - 48. [Abstract] [PDF]

				S. Zhou, A. Starkov, M. K. Froberg, R. L. Leino, and K. B. Wallace Cumulative and Irreversible Cardiac Mitochondrial Dysfunction Induced by Doxorubicin Cancer Res., January 1, 2001; 61(2): 771 - 777. [Abstract] [Full Text]

				G.-X. Wang, X.-B. Zhou, and M. Korth Effects of Mitoxantrone on Excitation-Contraction Coupling in Guinea Pig Ventricular Myocytes J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 501 - 508. [Abstract] [Full Text]

				M. Yoshida, Y. Maehara, and K. Sugimachi MST-16, a Novel Bis-dioxopiperazine Anticancer Agent, Ameliorates Doxorubicin-induced Acute Toxicity While Maintaining Antitumor Efficacy Clin. Cancer Res., December 1, 1999; 5(12): 4295 - 4300. [Abstract] [Full Text] [PDF]